Open AccessPB2307: A MULTICENTER, RANDOMIZED, OPEN‐LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
Author(s) -
Mingot Castellano M. E.,
Bradbury C. A.,
Rosso Fernández C.,
Thomas I.,
AlvarezRomán M. T.,
Canaro M.,
Caparrós Miranda I. S.,
Cappechi M.,
Carpenedo M.,
Evans G.,
GonzálezLopéz J. T.,
GonzálezPorras J. R.,
Jarque Ramos I.,
LozanoAlmela M. L.,
Lopez Fernandez M. F.,
Lowe G.,
Lyall H.,
Pascual Izquierdo C.,
Pavord S.,
Rayment R.,
Roberts P.,
Rosique Cortina P.,
SánchezGonzález B.,
Santoro C.,
Talks K.,
ValcarcelFerreiras D.,
Zaja F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000852056.49558.d7
Subject(s) - romiplostim , medicine , dexamethasone , tolerability , clinical endpoint , immune thrombocytopenia , randomized controlled trial , adverse effect , thrombopoietin , platelet , genetics , stem cell , haematopoiesis , biology